Self-assembling peptide scaffolds in the clinic

Fabrizio Gelain, Zhongli Luo, Marika Rioult and Shuguang Zhang

Well-defined scaffold hydrogels made of self-assembling peptides have found their way into clinical products. By examining the properties and applications of two self-assembling peptides—EAK16 and RADA16—we highlight the potential for translating designer biological scaffolds into commercial products.

npj Regenerative Medicine (2021)6:9; https://doi.org/10.1038/s41536-020-00116-w

INTRODUCTION

Self-assembling peptide (SAP) scaffolds can be traced back to the fundamental discoveries made in 1951 by Pauling et al., who reported the molecular structures of the most fundamental motifs of proteins, namely the alpha-helix and the beta-sheet. The beta-sheet structure is the molecular basis of most SAP nanofiber scaffolds. However, it was not until the serendipitous discovery of a SAP as a repeating segment in the yeast protein Zutin in 1990 that the concept of peptides as well-defined nanomaterials was recognized. Since then, peptide nanofiber scaffolds have been designed as 3D scaffolds for the serum-free culturing of tissue and stem cells, for reparative and regenerative medicine and for accelerated wound healing and surgery. In this perspective, we examine the translational advances and commercialization of SAP-based nanomaterials by highlighting the properties and design of two peptides that are used in clinical applications, that is, EAK16- and RADA16-derived SAPs. Numerous other non-SAP hydrogels have been used in various clinical and preclinical applications in last few decades. Readers who are interested in other nonpeptide biomaterials for clinical uses should consult the extensive literature.

The translation of SAP nanofiber scaffolds into commercial products requires: (1) they provide a functional improvement over existing products on the market; (2) they are marketable at a cost similar or lower than the competing products; (3) they can be scaled up at a reasonable cost; (4) they are completely harmless to animal and human tissues; (5) they are beneficial for medical and societal needs; and (6) they are approved by appropriate regulatory agencies for widespread use.

DESIGNING PEPTIDE NANOFIBER BUILDING BLOCKS

The first SAP, EAK16, was unexpectedly discovered as an unusual repetitive segment (AEEAEEKAAEAK) in a natural yeast protein. To mimic the self-assembly properties of this naturally occurring SAP, two variants, RADA16-II and RADA16-I, were synthesized using natural L-amino acids and solid phase chemistry. These sequences were inspired by the almost ubiquitous presence of RGD (arginine, glycine, aspartic acid) as a functional motif from fibronectin and other extracellular matrix proteins, stimulating adhesion and survival of cultured cells in vitro, where A (alanine) was chosen instead of G (glycine) to reduce flexibility of the peptide chain and warrant appropriate stability of the self-assembled nanofibers.

The D-form amino acids were used for the design of chiral D-form SAPs, because chiral D-peptides are resistant to L-protease degradation, enabling their application in vivo. In general, the structure of SAPs can be regulated by the amino acid sequence, the peptide concentration, pH, temperature, and the ionic composition of the medium. Fine-tuning of these conditions allows the design of dynamic peptide structures as well as their self-assembly process and formation of nanostructures.

SAP NANOFIBER SCAFFOLDS FOR CELL REPAIR AND REGENERATION

SAPs fulfill many of the engineering requirements for tissue scaffolds, in particular, biomimetic tunability. The mechanical tunability and 3D spatial organization of SAPs make them ideal building blocks of scaffolds for in vitro 3D tissue cell culture, in which they can serve as soft fillers embedded in stiffer synthetic biocompatible biopolymers. In general, to be useful for tissue engineering, SAP scaffolds have to mimic the biomechanics of the specific tissue type, display multiple functional motifs to allow interaction with cells and/or cytokines involved in the regenerative process, have a bioabsorption time compatible with tissue regeneration kinetics, display nanostructures and porosity to facilitate tissue infiltration and cytokine diffusion, and self-assemble in response to a stimulus compatible with other biological scaffolds.

Owing to the ease of biomimetic functionalization, their nanostructured morphology, their mechanical tunability, their high content of water or medium (≈99%), their permeability, and, most importantly, their excellent transparency, SAPs are becoming an important synthetic microenvironment for cell and stem cell differentiation in vitro. To achieve the required mechanical properties favoring cell culturing, transplant engraftment and tissue regeneration SAPs: (1) can be dissolved at different concentrations (e.g., from 1 to 5% v/w); (2) can be mixed with multibranch SAPs sharing the same self-assembling backbones; (3) can be cross-linked with either natural or synthetic cross-linkers; and (4) lastly, they can be point-mutated at their sequence, altering the overall hydrophobic/hydrophilic balance.

1Institute for Stem-Cell Biology, Regenerative Medicine and Innovative Therapies (ISBREMIT), IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy. 2Center for Nanomedicine and Tissue Engineering (CNTET), ASST Grande Metropolitano Niguarda, 20162 Milan, Italy. 3College of Basic Medical Sciences, Molecular Medicine and Cancer Research Centre, Chongqing Medical University, Chongqing 400016, China. 4Department of Biomedical Engineering, Drexel University, Philadelphia, PA 19104, USA. 5Laboratory of Molecular Architecture, Media Lab, Massachusetts Institute of Technology, Cambridge, MA 02139-4073, USA. 6These authors contributed equally: Fabrizio Gelain, Zhongli Luo. 7Email: f.gelain@css-mendel.it; Zhongliluo@163.com; Shuguang@MIT.EDU

Published in partnership with the Australian Regenerative Medicine Institute
cells in serum-free 3D systems. Double functionalization of proliferation, differentiation, and neurite outgrowth of neural stem cells can be optimized to allow the formation of a dense 3D network of astrocytes, and cholinergic neurons have been successfully cultured in and oligodendrocytes in long-term cultures. GABAergic, glutamatergic, and cholinergic neurons in nervous tissue cells are highly sensitive to the mechanical properties and bioactivity of the surrounding microenvironments. The stiffness of nervous tissue (100–1000 Pa) is similar to that achievable with SAP nanofiber scaffolds. Moreover, SAPs can be functionalized with laminin moieties, which is a key protein in the extracellular matrix of brain tissue. Therefore, SAP scaffolds offer ideal properties for the culture of nervous tissue. SAP scaffolds can also match the flexibility and compliance of peripheral nerves as well as the 3D spatial cytoarchitecture of the central nervous, which are a key to successful nerve regeneration in vitro. For example, nervous tissue regeneration and functional recovery can be achieved using RADA16-I functionalized with the BMHP1 active motif, preassembled RADA16-I, and LDDLK12 seeded and precultured in vitro with NSCs. Then, the functionalized RADA16-I is loaded with a mix of prorregenerative cytokines and injected into electrosyn microchannels (Fig. 2). Diluted SAPs (with the lowest G’) allow diffusion within acutely injured spinal cord tissue without perturbing the preexisting neural circuitry, attenuate hematoma, and foster an increased number of regenerated axons, leading to the formation of electrically active neural networks.

Similarly, SAP scaffolds can be used to promote wound healing after surgical procedures, traumatic injury, chronic diabetic ulcers, and bedsores. SAP scaffolds do not elicit any noticeable adverse immune responses or inflammatory reactions, as they are made of pure synthetic amino acid without animal-derived components or chemical, biological, or toxic contaminants. Therefore, SAP scaffolds have been approved for wound healing applications in humans, with additional trials for several indications already planned or launched for human tooth wound healing and skin wound healing. Chiral SAP scaffolds can further incorporate components for disinfecting and protecting superficial wounds and abrasions.

**RADA16 IN SURGICAL USE**

The SAP RADA16 (Fig. 1) is sold as a hemostatic agent for surgery (PuraStat®) and as a reagent for life science research, PuraMatrix® (1% solution) (Fig. 3). PuraMatrix® is
CHIRAL D-FORM SAP SCAFFOLDS

Chiral self-assembling SAPs were designed using D-amino acids or a combination of alternating D- and L-amino acids, such as d-EAK16. However, the secondary structure of d-EAK16 is less stable than that of l-EAK16. The stability can be tailored by adjusting the temperature, pH, and salts. Nano fibers of self-assembling peptides scaffold hydrogels are subsequently tested with cells (either to be transplanted or from the target tissue) in vitro to verify cytotoxicity and biomimetic properties of the novel construct. Synthetic self-assembling peptides are tailored into 3D constructs with densely seeded cells (image courtesy of Amanda Marchini), potentially leading to organoids in long-term cultures in serum-free conditions. Selected self-assembling hydrogels (seeded with cells or loaded with drugs) are injected or positioned (after self-assembling) in vivo animal models of the target pathology. All steps provide essential data for subsequent clinical approval.

SAPs have been accidentally discovered, and have since been translated into a variety of clinically applicable products. Key to the successful and rapid translation of SAPs was the focus on clinical needs and commercialization, which can be achieved by focusing on regulatory questions and commercialization requirements early in the research process.

OTHER SAP SCAFFOLDS IN CLINICAL TRIALS

Other SAP-based products have been tested in clinical trials and are already available on the clinical market in recent years. Among them, a clinical safety trial was conducted with P11-4 SAP in the treatment of early dental care lesions, showing negligible adverse effects not related to the treatment and a significant enamel biomineralization within the lesion cavities. Later on, in a prospective, randomized clinical trial, the same SAP was demonstrated to be effective, and significantly better than standard treatments, in regenerating decayed enamel, favoring the formation of novel hydroxyapatite at the bottom of early carious lesions.

Recently, another SAP, named T45K, was tested for safety and efficacy as hemostat solution for small-size skin wounds in a blind clinical trial. Authors showed that with T45K, if compared to control treatment, a faster time to hemostasis and superior wound healing could be achieved also in patients undergoing antiplatelet therapy. On the other hand, safety profiles were similar to control. The lack of adverse effects in all clinical trials of SAPs seems to point out the promising potential and safety of such biomaterials in clinics.

RADA-LIKE SAPS VS OTHER SAPS

The field of self-assembling is rapidly expanding, and a number of alternative sequences have been developed, yielding to

Fig. 2 The assembly line of self-assembling peptides toward clinics. a Molecular modeling for both all-atom and coarse-grained simulations of self-assembling peptides featuring different functionalizations are necessary to verify the self-assembling propensity and solubility of new sequences. b Nanofibers of self-assembling peptides scaffold hydrogels are subsequently tested with cells (either to be transplanted or from the target tissue) in vitro to verify cytotoxicity and biomimetic properties of the novel construct. c Synthetic self-assembling peptides are tailored into 3D constructs with densely seeded cells (image courtesy of Amanda Marchini), potentially leading to organoids in long-term cultures in serum-free conditions. d Selected self-assembling hydrogels (seeded with cells or loaded with drugs) are injected or positioned (after self-assembling) in vivo animal models of the target pathology. All steps provide essential data for subsequent clinical approval.

Fig. 3 PuraStat® made of self-assembling peptide nanofiber scaffolds and PuraStat® accessories. a 5 ml syringe with attached nozzle applicator, ready for use as a hemostatic agent during surgery after opening of the packaging and attachment of the nozzle applicator. b Endoscopic nozzle (160 mm) attached to a PuraStat® syringe. c Laparoscopic nozzle.
heterogenous self-assembled nanostructures such as nanovesicles, nanorods, nanotubes, or nanoribbons. For a detailed description of other SAP-based therapies not yet into clinical testing, we link the reader to dedicated comprehensive reviews while we focus our attention on peculiarities of RADA16/LDLK12/EAK12 in respect to other widely published SAPs. RADA16 molecules can be easily functionalized at one or both termini by simply extending their backbone sequence and interspacing it with a pool of Gly: this process, with some limits, allow a considerable set of choices of functional motifs since the self-assembling backbone sequence show strong propensity to self-assemble and is less perturbed by functionalization than, for example, peptide amphiphiles and Fmoc-modified short SAPs, where overall peptide length/polarity affect the stability and the final self-aggregated structure. Also, provided that the same self-assembling backbone is used, RADA16-like peptides allow for the concurrent exposure of a number of different functional motifs within the same scaffold: this is useful to address, for example, pathologies with a complex set of biological pathways involved such as spinal cord regeneration. In respect to coassembling peptides (e.g., LKLK12 and LDLD12), RADA16-like peptides are neutral at neutral pH and require a shift of solvent pH to trigger their gelation, while the former just need the copresence of both species. Also, in respect to BMHP1-derived SAPs, capable of forming complex and hierarchically self-assembled nano- and microstructures, RADA6-like SAPs usually give rise to flat cross-beta fibers, occasionally paired together: this can allow a better control of scaffold properties (i.e., porosity, stiffness, etc.). Like all other SAPs, RADA16 show fragile behavior and limited mechanical properties narrowing their field of application to soft or medium-soft tissues, however this can be overrun via chemical cross-linking. Lastly, in respect to BMHP1-derived SAPs, RADA16-like SAPs do not show significant self-healing properties.
which may be detrimental for some regenerative medicine applications.

SOLVING MANUFACTURE BOTTLENECKS

One of the key issues to be solved for SAP nanofiber scaffold commercialization is affordable scale-up production. For human use, GMP must be followed and be compliant with the relevant requirements of regulatory agencies including ubiquitous quality control requirements through all steps of the product’s development, manufacturing, warehousing, marketing, sales or distribution, after sales services, workforce and customer training, and operational systems and processes. Despite the unique and commercially appealing properties of SAPs, developing viable and affordable SAP-based products has taken almost a decade. Because in the early 2000s peptide production was still too expensive and complicated for initial small-scale industrial production, chemical peptide synthesis turned out to be most efficient. Chemical peptide synthesis also yields a well-characterized, pure product that can be produced with high enough batch-to-batch consistency for medical use.

The high cost of SAPs production narrowed early on any possible applications to the health industry and use in human medicine. SAPs promise potential success in tissue regeneration, sustained drug delivery, and surgical applications, such as stasis of body fluids or reduction of adhesions after surgery. A further advantage of synthetic SAPs is that regulatory authorities may accept them as medical devices, thereby allowing development of products in less time and with less capital. However, the production of small or lab-scale quantities of SAPs for nonhuman use can be achieved by conventional desktop peptide synthesizer and purified by a laboratory HPLC.

SAP manufacturing methods have evolved over the last two decades, going from fixed, dedicated, investment-heavy production lines to conventional but modular production assemblies, to low-cost, single batch micro production setups. For research purposes only, PuraMatrix® (RADA16) is available in non-GMP grade from various vendors, including 3-D Matrix and others. The same applies to other research purpose polymeric systems which are indeed less expensive to manufacture. Again, compounds destined for medical purposes are subject to strict regulatory and quality control requirements that drive their cost up. In fact, it is not unusual that the chemical production cost alone may end up being lower than sum of all other costs involved in the production of a medical device product.

WORKING WITH REGULATORY AGENCIES

For any products derived from nanotechnology to be successfully commercialized as medical products, it is critical to work closely with regulatory agencies. Although slowly converging over the last two decades, the regulatory environments among the largest health markets, including the USA, Japan, and Europe, remained different until very recently, at least for medical devices. Simplified market approval of medical devices in any of the world’s larger markets is based on regulatory compliance with relevant laws, on demonstrated safety and performance in human use as evidenced by biosafety studies and clinical trials, and on a quality management system that monitors the product’s R&D, GMP manufacturing, marketing, sales, and use. Interestingly, while market approval of SAPs was easier to achieve in Europe than in the USA until a few years ago, market approval in Europe today has become difficult and slower. This is the result of three linked developments: the stricter European Medical Device Regulations (MDR) replacing the simpler and obsolete Medical Device Directives (93/42/EEC) on May 26, 2021; harmonized quality management guidelines ISO13485:2016 replacing the simpler ISO13485:2012; and over half of all medical device-assessing notified bodies—the organizations mandated by member states of the EU to assess the conformity of certain products before being placed on EU markets (CE-mark)—disappearing as a result of these changes, whether for economic or operational reasons or because they were unable to become certified under the new MDR.

The number of market approval requests did however not decrease as much, and was led partially by the disappearance of small medical device companies that could no longer cope with the new regulations. Overall, it is expected that new SAP-based medical products will start to appear increasingly in the U.S. market already this year, while SAPs have been sold as medical devices on the European markets (e.g., PuraStat®) since 2015. As a consequence of these changes, regulatory and quality management aspects of medical devices must be planned even earlier, at the research stage before product development is being considered. As in good design practices, the design of the product should be reverse engineered starting from customer and user input while being continually subject to the quality management system. The product needs to be designed for manufacturing and here, too, quality management is intrinsically part of this process.

SAPs have the advantage that as long as they are inert and do not show distinct biologic activity, they may be regulated as medical devices in most jurisdictions. Medical devices may be approved by the USFDA via a premarket approval process (PMA; Code of Federal Regulations 21 CFR Section 814) or a premarket notification 510(k) (21 CFR 807). Through a PMA, a medical device is demonstrated to be safe and effective for the patient or end user. PMAs require substantial clinical trials. According to the FDA, the goal of a 510(k) instead is “to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device.” The need for clinical trials is usually reduced and approval takes less time and is less expensive. In many cases, a 510(k) is a more desired path to commercialization than a PMA process.

THE FUTURE OF SAPS

Since the initial discovery of SAPs, several clinical applications have been brought to the market. The SAP material continues to have great potential to be exploited into beneficial products. We have only scratched the surface of the possibilities for development. The coming decades promise to show the fulfillment of the potential of this class of materials.

METHODS

Designer peptide synthesis and scaffold preparation

All self-assembling peptides were dissolved in distilled sterile water ( Gibco) at a final concentration of 1% (v/w) (10 mg/ml) and sonicated for 30 min before use.

Cell cultures

Neural precursor cultures are established and expanded as previously described. Briefly, neural precursors isolated from the subventricular zone of 8-week-old CD-1 albino mice striata, at passage 10, were used. Cell proliferation was performed in NS-A serum-free medium (Euroclone, Irvine, UK), in the presence of basic fibroblast growth factor (BFGF from PeproTech, Rocky Hill, NJ) and epidermal growth factor (EGF from PeproTech) at final concentrations of 10 and 20 ng/ml. The medium without growth factors was used as a basal medium. Bulk cultures were generated by mechanically dissociating neurospheres and plating cells in untreated flasks at the appropriate density (1 × 104 cells/cm2) every 4–5 days in the same growth medium. Cell counting and viability was performed at every passage, using trypan blue exclusion.
**Cell culture seeding**

Neural precursor cultures were established and expanded as described previously. In the case of adhesion and differentiation tests, cell seeding (at a concentration of 2–8 × 104 cells/cm2) was performed 2 days after the last mechanical dissociation in order to seed the maximum percentage of stem cells. Cells were seeded on the top surface of each assembled scaffold, where they were able to settle into the nanofiber matrices. Over time cells penetrate the self-assembled layer.

In the case of SEM imaging, cells were acutely mixed with 8 μl of aqueous gel solution at a final concentration of 5–8 × 103 cells/μl in a total final volume of 10 μl per sample. Self-assembly was then initiated by adding basal medium slowly and placing seeded scaffolds mounted on copper grids (Ted Pella Inc.) at +37 °C for 30 min. Cells were thus already embedded in the matrices.

For both adhesion and differentiation tests and SEM imaging, cells were cultured with basal medium supplemented with bFGF (10 ng/ml), added to enhance neuronal progeny differentiation. After 3 days, the medium was shifted to a medium containing leukemia inhibitory factor (LIF, Chemicon) (20 ng/ml) and brain-derived neurotrophic factor (BDNF, Peprotech) (20 ng/ml) to pursue the neuronal and glial population maturation in NSC progeny. Cells were fed every 3 days with the same fresh culture medium.

**Cell proliferation assay**

MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) was prepared in a 5 mg/ml stock solution in PBS, then added to the culture medium in a ratio of 1:100. After 1-h incubation at +37 °C, the MTT solution was removed and the insoluble formazans crystals were dissolved by soaking scaffolds and cells for 15 min in 250 μl of dimethylsulfoxide. The absorbance was measured by using a Vmax microplate reader ( Molecular Devices, Sunnyvale, CA) at a wavelength of 550 nm.

To assess the viability of NSCs seeded on scaffolds made of various peptides, a quantitative method, MTT assay (Sigma), was used. Four independent experiments comprising three replicates each were performed. For this viability test, the direct proportional linearity between the optical density and the viability/metabolic activity of the cell populations was assessed from verifying the linearity of five different standard curves at six increasing cell concentrations, ranging from 5 × 103 to 5 × 105 cells/well. Results are expressed as percent increase in cell population from the population seeded on day 1.

Cell viability and differentiation assay tests were conducted by pouring aqueous solution of functionalized SAPs hydrogel (30 μl per well) so as to evenly cover the bottom surface of each well (~30 μm gel layer thickness) of 96 multiwell plates (BD Biosciences). In the case of SEM imaging both for Matrigel and the peptide hydrogel, the total amount of biomaterial was reduced to 10 μl. The experimental protocol included control tests conducted with nonfunctionalized RADA16 (negative control) and Matrigel coating (positive control). RADA16 and other functionalized peptides hydrogel: poured 30 μl/well of a 1% (w/v) distilled sterile water solution, followed by slow addition of 200 μl/well of basal medium. Allowed to self-assemble at 37 °C for 30 min and rinsed once with control medium to wash away any residual acid residues remaining from peptide synthesis. Matrigel GF-reduced (from EHS sarcoma, BD Biosciences): diluted 1:100 in basal medium, poured at 100 μl/well, 30 min incubation at 37 °C, then rinsed with basal medium. In the case of SEM imaging, no dilution was adopted in order to guarantee the necessary stiffness for a three-dimensional scaffold.

**Immunocytochemistry**

Neuronal and glial differentiation was assessed by double and single immunostaining with lineage-specific antibodies: anti-Nestin (1:150, Chemicon) for progenitor cells, rabbit anti-β-tubulin (1:500, Covance) for neurons, and mouse anti-β-glial fibrillary acidic protein (1:200, Chemicon) for astrocytes. Primary antibodies were then stained with secondary ALEXA 488 goat anti-mouse (1:1000, Molecular Probes) and CY3 AffiniPure F(ab’)2 anti-rabbit IgG antibodies (1:100, Jackson Immuno Research). Cell nuclei were counterstained with DAPI (Molecular Probes). The samples were then examined by inverted fluorescence microscope. Quantitative analyses were performed by counting 100–300 cells for each of ten nonoverlapping (and randomly chosen) fields. Four independent experiments comprising two replicates each were performed.

**SEM sample preparation**

Samples were prepared as described previously. Briefly, the samples were soaked in 5% glutaraldehyde at 4 °C for 2 h, followed by washing in MilliQ water and slow sequential dehydration steps in 10% increments of ethanol for 5 min each. Samples were then placed in pressurized liquid CO2/siphon for 1 h using a CO2 critical point dryer (Tousims). Scaffolds were next sputter-coated with gold-palladium particles (~10 nm gold coating thickness), mounted on a copper grid and examined.

**In vitro neural stem cell cultures**

3D scaffolds were self-assembled on cell culture inserts, PET membrane, 1.0 μm pore size (BD Biosciences). SAPs were dissolved in sterile distilled water (GIBCO) to double the desired concentration the day before cell plating. On the day of scaffold preparation, 12 μl of each SAP was diluted with 12 μl of glucose 8%, to balance cellular osmolarity, to the final desired concentration. A volume of 24 μl of each SAP was gently mixed with 8 μl of culture medium containing a cell density of 4000 cells/μl, in a total of 3.2 × 104 murine neural stem cells. The mixture was placed on the insert membrane, subsequently placed in the well containing basal cell culture medium supplemented with 20 ng/ml LIF (Chemicon), and 20 ng/ml BDNF (Peprotech) to foster cell differentiation and allowed to self-assemble at 37 °C. The culture medium was replaced every 3 days. Cells were subsequently labeled with live/dead cell assay (Molecular Probes) following the provided protocol in the datasheet.

**High-density 3D cell seeding**

Before seeding, NSCs were separately cultured at density of 10⁴ cells/cm² using serum-free medium in the presence of bFGF (PeproTech) and EGF (PeproTech) at final concentrations of 10 and 20 ng/ml, respectively. Neurospheres were mechanically dissociated every 10 days in the same growth medium. Briefly, peptide hydrogel (dissolved 1% w/v in dH₂O, GIBCO) was mixed with
sucrose, NaOH, and culture medium containing a cell density of 4.5 × 10^4 cells/ml. A droplet of 40 ml was placed in a 24-well and serum-free medium supplemented with BFGF (20 ng/ml) was added to generate 3D scaffolds. At 2 days in vitro, medium was shifted with a basal medium supplemented with LIF (20 ng/ml, Chemicon) and BDNF (20 ng/ml, PeproTech). Fresh medium was replaced every 3 days.

Hydrogel implants for nervous regeneration
SAPs were dissolved in sterile distilled water (GIBCO) at 1% (w/v) concentration. Depending on the tested regenerative medicine application, a dedicated injury has to be imposed to the animal in order to provide space for scaffold placement. SAP can be injected or preassembled into electrop spun microchannels (made of synthetic polymers such PCL and PLGA or of cross-linked SAPs) before placement. In the latter case, an additional dose of pure SAP into the implant site is recommended in order to better fill the gaps among the channels and provide a continuum scaffold filling the site of injury. Scaffolds can be later examined, after animal perfusion, with standard histology techniques.

DATA AVAILABILITY
The datasets generated during and/or analyzed during these studies are available from the corresponding author on reasonable request.

Received: 28 May 2020; Accepted: 3 December 2020
Published online: 17 February 2021

REFERENCES

1. Pauling, L., Corey, R. B. & Branson, H. R. The structure of proteins; two hydrogen-bonded helical configurations of the polypeptide chain. Proc. Natl Acad. Sci. USA 37, 205–211 (1951).
2. Pauling, L. & Corey, R. B. Configurations of polypeptide chains with favored orientations around single bonds: two new pleated sheets. Proc. Natl Acad. Sci. USA 37, 729–740 (1951).
3. Zhang, S., Holmes, T., Lockshin, C. & Rich, A. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc. Natl Acad. Sci. USA 90, 3334–3338 (1993).
4. Langer, R. & Tirrell, D. Designing materials for biology and medicine. Nature 428, 487–492 (2004).
5. Langer, R. Synthetic tissue. Mol. Front. J. 1, 92–98 (2017).
6. Langer, R. Controlling the movement of molecules. Q. Rev. Biophys. 52, 1–21 (2019).
7. Vega, A. et al. Long-term glycemic control using polymer encapsulated human stem cell-derived beta cells in immune-competent mice. Nat. Med. 22, 306–311 (2016).
8. Vega, A. et al. Combinatorial development of hydrogels that mitigate the foreign body response in primates. Nat. Biotech. 34, 345–352 (2016).
9. Zhang, S. et al. Self-complementary oligopeptide matrices support mammalian cell attachment. Biomaterials 16, 1385–1393 (1995).
10. Holmes, T. C. et al. Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc. Natl Acad. Sci. USA 97, 6728–6733 (2000).
11. Alipour, M. et al. Recent progress in biomedical applications of RGD-based ligand: from precise cancer theranostics to biomaterial engineering: a systematic review. J. Biomed. Mater. Res. A 108, 839–850 (2020).
12. Luo, Z., Zhao, X. & Zhang, S. Structural dynamic of a self-assembling peptide d-EAK16 made of only D-amino acids. PLoS ONE 3, e2364 (2008).
13. Miroshnikova, Y. A. et al. Engineering strategies to recapitulate epithelial morphogenesis within synthetic three-dimensional extracellular matrix with tunable mechanical properties. Phys. Biol. 8, 026013 (2011).
14. Gelain, F., Bottai, D., Vescovi, A. & Zhang, S. Designer self-assembling peptide nanofiber scaffolds for adult mouse neural stem cell 3-dimensional cultures. PLoS ONE 3, e119 (2008).
15. Shah, R. N. et al. Supramolecular design of self-assembling nanofibers for cartilage regeneration. Proc. Natl Acad. Sci. USA 107, 3293–3298 (2010).
16. Cunha, C., Panseri, S., Villa, O., Silva, D. & Gelain, F. 3D culture of adult mouse neural stem cells within functionalized self-assembling peptide scaffolds. Int. J. Nanomed. 6, 943–955 (2011).

F. Gelain et al.

17. Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs stem cell lineage specification. Cell 126, 677–689 (2006).
18. Pugliese, R., Fontana, F., Marchini, A. & Gelain, F. Branched peptides integrate into self-assembled nanostructures and enhance biomechanics of peptide hydrogels. Acta Biomater. 66, 258–271 (2017).
19. Pugliese, R., Maleki, M., Zuckermann, R. N. & Gelain, F. Self-assembling peptides cross-linked with genipin: resilient hydrogels and self-standing electrop spun scaffolds for tissue engineering applications. Biomater. Sci. 7, 76–91 (2018).
20. Pugliese, R., Marchini, A., Saracino, G. A. A., Zuckermann, R. N. & Gelain, F. Cross-linked self-assembling peptide scaffolds. Nano Res. 11, 586–602 (2017).
21. Chen, C. et al. Tuning gelation kinetics and mechanical rigidity of β-hairpin peptide hydrogels via hydrophobic amino acid substitutions. ACS Appl. Mater. Interfaces 6, 14360 (2014).
22. Silva, D. et al. Synthesis and characterization of designed BMH1-derived self-assembling peptides for tissue engineering applications. Nanoscale 5, 704 (2013).
23. Sun, Y. et al. Functional self-assembling peptide nanofiber hydrogels designed for nerve degeneration. ACS Appl. Mater. Interfaces 8, 2348–2359 (2016).
24. Gelain, F. et al. New bioactive motifs and their use in functionalized self-assembling peptides for NSC differentiation and neural tissue engineering. Nanoscale 9, 2946–2957 (2012).
25. Caprini, A. et al. A novel bioactive peptide: assessing its activity over murine neural stem cells and its potential for neural tissue engineering. N. Biotechnol. 30, 552–562 (2013).
26. Marchini, A. et al. Multifunctionalized hydrogels foster NSC maturation in 3D cultures and neural regeneration in spinal cord injuries. Proc. Natl Acad. Sci. USA 116, 7483–7492 (2019).
27. Gelain, F. et al. Transplantation of nanostructured composite scaffolds results in the regeneration of chronically injured spinal cords. ACS Nano 5, 227–236 (2011).
28. Cheng, T. Y., Chen, M. H., Chang, W. H., Huang, M. Y. & Wang, T. W. Neural stem cells encapsulated in a functionalized self-assembling peptide hydrogel for brain tissue engineering. Biomaterials 34, 2005–2016 (2013).
29. Chen, J. et al. Enhanced osteogenesis of human mesenchymal stem cells by periodic heat shock in self-assembling peptide hydrogel. Tissue Eng. Part A 19, 716–728 (2013).
30. Li, L. et al. Biomimetic scaffolds: 3D molecularly functionalized cell-free biomimetic scaffolds for osteochondral regeneration. Adv. Funct. Mater. 29, 1970036 (2019).
31. Boopathi, A. V. et al. The modulation of cardiac progenitor cell function by hydrogel-dependent Notch1 activation. Biomaterials 35, 8103–8112 (2014).
32. Giri, S. et al. Three dimensional cultures of rat liver cells using a natural self-assembling nanoscaffold in a clinically relevant bioreactor for bioartificial liver construction. J. Cell Physiol. 227, 313–327 (2012).
33. Bartlett, R. D., Choi, D. & Phillips, J. B. Biomechanical properties of the spinal cord: implications for tissue engineering and clinical translation. Regen. Med. 11, 659–673 (2016).
34. Gorley, A. et al. Mechanics of the brain: perspectives, challenges, and opportu

npj Regenerative Medicine (2021) 9

Published in partnership with the Australian Regenerative Medicine Institute
ACKNOWLEDGEMENTS
The authors greatly appreciate their students, postdocs, and 3D Matrix colleagues to make significant contributions to the original research that eventually translated the unexpected discovery to many useful medical products that benefit mankind. The authors would also like to thank Dorrie Langsley for carefully checking the English and for making constructive suggestions.

AUTHOR CONTRIBUTIONS
F.G., Z.L., and S.Z. conceived this manuscript. All authors wrote the manuscript, designed the figures, and edited the manuscript.

COMPETING INTERESTS
F.G. is an employee of IRCCS Casa Sollievo della Sofferenza (a hospital) in Milan, Italy, and was supported by the “Ricerca Corrente 2018–2020” funding granted by the Italian Ministry of Health, by the “5x1.000” voluntary contributions, and by Revert Onlus. He is the cofounder of Nanomed 3D s.r.l. (Milan, Italy) and has shares in the company. Z.L. is an employee of Chongqing Medical University and was supported by the grant from the National Natural Science Foundation of China (Project Nos NSFC 31771101 and 31540019) and the Natural Science Foundation of CQ CSTC (Key) under Grant (Project No. CSTC2015JCYJBX0072). He is the cofounder of Sciobio, Ltd., Chengdu, China, and has shares in the company. M.R. is an employee of 3-D Matrix, Inc. He is the Director and global IP of the 3-D Matrix Group, and has shares in the company. S.Z. is an employee of Massachusetts Institute of Technology. He is the cofounder of 3-D Matrix, Inc. and is also a scientific advisor and has shares in the company.